Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 6-7, Juin–Juillet 2012
Page(s) 605 - 611
Section M/S Revues
DOI http://dx.doi.org/10.1051/medsci/2012286013
Publié en ligne 16 juillet 2012
  1. Coquet JM, Kyparissoudis K, Pellicci DG, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007 ; 178 : 2827–2834. [PubMed]
  2. Parrish-Novak J, Dillon S, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 ; 408 : 57–63. [CrossRef] [PubMed]
  3. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008 ; 26 : 57–79. [CrossRef] [PubMed]
  4. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003 ; 102 : 4090–4098. [CrossRef] [PubMed]
  5. Caruso R, Fina D, Peluso I, et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007 ; 178 : 5957–5965. [PubMed]
  6. Distler JH, Jungel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005 ; 52 : 856–864. [CrossRef] [PubMed]
  7. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004 ; 173 : 657–665. [PubMed]
  8. Ozaki K, Kikly K, Michalovich D, et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 2000 ; 97 : 11439–11444. [CrossRef]
  9. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002 ; 72 : 856–863. [PubMed]
  10. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008 ; 20 : 295–301. [CrossRef] [PubMed]
  11. Battegay M, Moskophidis D, Rahemtulla A, et al. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994 ; 68 : 4700–4704. [PubMed]
  12. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994 ; 68 : 8056–8063. [PubMed]
  13. Ou R, Zhou S, Huang L, Moskophidis D. Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells. J Virol 2001 ; 75 : 8407–8423. [CrossRef] [PubMed]
  14. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009 ; 324 : 1569–1572. [CrossRef] [PubMed]
  15. Frohlich A, Kisielow J, Schmitz I, et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009 ; 324 : 1576–1580. [CrossRef] [PubMed]
  16. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009 ; 324 : 1572–1576. [CrossRef] [PubMed]
  17. Barker BR, Gladstone MN, Gillard GO, et al. Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol 2010 ; 40 : 3085–3096. [CrossRef] [PubMed]
  18. Publicover J, Goodsell A, Nishimura S, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011 ; 121 : 1154–1162. [CrossRef] [PubMed]
  19. Pallikkuth S, Pilakka Kanthikeel S, Silva SY, et al. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J Immunol 2011 ; 186 : 6173–6181. [CrossRef] [PubMed]
  20. Rankin AL, MacLeod H, Keegan S, et al. IL-21 receptor is critical for the development of memory B cell responses. J Immunol 2011 ; 186 : 667–674. [CrossRef] [PubMed]
  21. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010 ; 207 : 155–171. [CrossRef] [PubMed]
  22. Iannello A, Boulassel MR, Samarani S, et al. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J Immunol 2010 ; 184 : 114–126. [CrossRef] [PubMed]
  23. Iannello A, Tremblay C, Routy J, et al. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: Correlation with CD4+ T cell counts. Viral Immunol 2008 ; 21 : 385–388. [CrossRef] [PubMed]
  24. Chevalier MF, Julg B, Pyo A, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 2011 ; 85 : 733–741. [CrossRef] [PubMed]
  25. Yue FY, Lo C, Sakhdari A, et al. HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol 2010 ; 185 : 498–506. [CrossRef] [PubMed]
  26. Williams LD, Bansal A, Sabbaj S, et al. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol 2011 ; 85 : 2316–2324. [CrossRef] [PubMed]
  27. Iannello A, Boulassel MR, Samarani S, et al. IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication. J Leukoc Biol 2010 ; 87 : 857–867. [CrossRef] [PubMed]
  28. Parmigiani A, Pallin MF, Schmidtmayerova H, et al. Interleukin-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. Hum Immunol 2011 ; 72 : 115–123. [CrossRef] [PubMed]
  29. Abrams D, Lévy Y, Losso M, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009 ; 361 : 1548–1559. [CrossRef] [PubMed]
  30. Pallikkuth S, Rogers K, Villinger F, et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011 ; 29 : 9229–9238. [CrossRef] [PubMed]
  31. Rodrigues L, Nandakumar S, Bonorino C, et al. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response. Mol Immunol 2009 ; 46 : 1494–1504. [CrossRef] [PubMed]
  32. Cui FD, Asada H, Jin ML, et al. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice. Gene Ther 2005 ; 12 : 160–168. [CrossRef] [PubMed]
  33. Hu K, Dou J, Yu F, et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. Vaccine 2011 ; 29 : 1455–1462. [CrossRef] [PubMed]
  34. Van Leeuwen EM, Gamadia LE, Baars PA, et al. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J Immunol 2002 ; 169 : 5838–5843. [PubMed]
  35. Van Leeuwen EM, van Buul JD, Remmerswaal EB, et al. Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol 2005 ; 17 : 713–719. [CrossRef] [PubMed]
  36. Bolesta E, Kowalczyk A, Wierzbicki A, et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol 2006 ; 177 : 177–191. [PubMed]
  37. Leung-Theung-Long S, Guerder S. Les cellules Th17 : une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008 ; 24 : 972–976. [CrossRef] [EDP Sciences] [PubMed]
  38. Lambotte O. Les patients HIV controllers. Med Sci (Paris) 2012 ; 28 : 172–178. [CrossRef] [EDP Sciences] [PubMed]